Stage IV non–small cell lung cancer (NSCLC)

Slides:

Advertisements

Similar presentations

(A–C) Forms of non-small-cell carcinoma

Advertisements

Brief pain inventory. (Reproduced with permission from the University of Texas MD Anderson Cancer Center, Department of Symptom Research, Houston, TX.

Miliary tuberculosis. (A) Frontal chest radiograph demonstrates innumerable tiny nodules distributed throughout both lungs. There is a hazy opacity at.

CT and PET imaging in non-small cell lung cancer

Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan Case Rep Oncol 2013;6: DOI: /

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Same patient as in Fig The computed tomography positron emission tomography scan after four courses of hyperfractionated cyclophosphamide, vincristine,

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Large cell undifferentiated carcinoma of lung

CT scan of the chest. These axial images of the lower chest demonstrate the difference in lung and soft tissue windows. This patient has a history of congenital.

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment Tjeerd S. Aukema, MD, Renato.

Angiosarcoma. (A) The dermis has been largely replaced by highly atypical cells in this patient with angiosarcoma. (B) Malignant cells form bizarre vascular.

Squamous cell carcinoma

Eosinophilic pneumonia

Incidental significant finding on FDG-PET/CT

Nodular lymphocyte-predominant Hodgkin lymphoma. A

Advanced stage non–small cell lung cancer treatment algorithm

Algorithm for the classification of adult-onset primary myelodysplastic syndromes (MDS). This classification system is based on the 2008 criteria of the.

Algorithm for treatment of relapsed aggressive lymphomas (except high-grade or mantle cell lymphoma). MINE, mesna, ifosfamide, mitoxantrone, etoposide.

A-I. MD Anderson Cancer Center algorithms for Hodgkin lymphoma

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Staging of diffuse large B-cell lymphoma (DLBCL)

World Health Organization (WHO) three-step ladder oral analgesic program for managing cancer pain. Source: Chapter 48. Pain Management and Symptom Control,

Radioiodine scintigraphy of a patient with thyroid cancer shows abnormal 123I uptake in the neck and chest corresponding to iodine-avid metastases in the.

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies Marcelo F.K. Benveniste, MD, Cesar A.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Scott J. Adams, MD, Rajan Rakheja, MD, Rhonda Bryce, MD, Paul S

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Positron Emission Tomography in Lung Cancer

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

MET-Mutated NSCLC with Major Response to Crizotinib

Difficulties in Diagnosis and Management of Ectopic Cushing Syndrome

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Yasuo Miura, MD, PhD, Mitsuru Tsudo, MD, PhD Mayo Clinic Proceedings

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Nicholas W. Choong, MD, Robert S. Hellman, MD

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Positron emission tomography/computed tomography scans showed a mass lesion. a) Areas of cavitation were noted in the left lower lobe, encasing the segmental.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Kemp H Kernstine, MD, PhD, Kelley A McLaughlin,

Metastatic Lung Cancer to the Pancreas

Walter J. Scott, MD, James Shepherd, MS, Sanjiv Sam Gambhir, MD, PhD

Christopher Hazzard, BS, Andrea S. Wolf, MD, Mary B

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Mott Frank E. , MD, Sharma Neeraj , MD, Ashley Pandora CHEST

Presentation transcript:

Stage IV non–small cell lung cancer (NSCLC) Stage IV non–small cell lung cancer (NSCLC). Upon evaluation for back pain, this patient was found to have a pleural effusion (A, B), and biopsy revealed NSCLC. Positron emission tomography/computed tomography (C) revealed a 5.4- by 3.6-cm hypermetabolic mass in the right middle lobe, many small satellite fluorodeoxyglucose (FDG)-avid right lung nodules, and extensive FDG-avid pleural-based masses on the right (T4N0M1). No disease was found outside the chest. Source: Non–Small Cell Lung Cancer, The MD Anderson Manual of Medical Oncology, 3e Citation: Kantarjian HM, Wolff RA. The MD Anderson Manual of Medical Oncology, 3e; 2016 Available at: http://accessmedicine.mhmedical.com/DownloadImage.aspx?image=/data/books/1772/kantmmo3_ch18_f017.png&sec=121898440&BookID=1772&ChapterSecID=121898346&imagename= Accessed: October 21, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved